SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
RMG ML Sports Holdings disclosed the consummation of its IPO on June 11, 2026, issuing 20,000,000 units at $10.00 per unit for $200 million in gross proceeds, followed by partial exercise of the over-allotment option for 1,650,000 additional units on June 15, 2026, generating $16.5 million more. This is a material dilutive issuance of equity securities in a public offering context, with total proceeds of $216.5 million placed in trust.
View raw filing on EDGAR →T3 Defense disclosed the sale of 17,294,784 shares of common stock to Esousa Group Holdings, LLC for $4,545,236 in aggregate proceeds pursuant to a securities purchase agreement and an equity line program. The issuance represents a substantial dilution to existing shareholders (approximately 18% of the 94.8 million outstanding shares as of the filing date) and was made under a registered offering, consistent with a dilutive equity issuance event.
View raw filing on EDGAR →Roma Green Finance entered into an At the Market Offering Agreement on June 15, 2026, authorizing the sale of up to US$200 million in Class A ordinary shares through H.C. Wainwright & Co. as sales agent. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, material to investors as it represents a significant potential dilution to existing shareholders and a material capital-raising activity.
View raw filing on EDGAR →Bandwidth Inc. announced a proposed private offering of $275 million in convertible senior notes pursuant to Rule 144A, which is a material unregistered equity issuance. Convertible notes are inherently dilutive to existing shareholders upon conversion, and a $275 million offering represents a significant capital raise that would materially affect investor assessment of the company's capital structure and equity dilution risk.
View raw filing on EDGAR →Enhanced Group Inc. entered into a securities purchase agreement on June 14, 2026, to issue 12,853,468 shares of Class A common stock and accompanying warrants for approximately $50 million in gross proceeds. The private placement, which requires stockholder approval due to potential dilution exceeding 19.99% of outstanding shares, was announced via press release and includes anti-dilution adjustments for 24 months.
View raw filing on EDGAR →Conversion of approximately 103 million shares of Series Preferred Stock into Class A and Class B common stock in connection with the Company's IPO closing on June 15, 2026, representing a material dilutive event that fundamentally alters the capital structure.
View raw filing on EDGAR →Vivakor converted $103,100.78 in convertible promissory notes into 355,979 shares of common stock in an unregistered private placement under Section 4(a)(2). The underlying Lender Notes total $5.1 million in principal, representing a material dilutive issuance to existing shareholders.
View raw filing on EDGAR →The 6-K discloses termination of an at-the-market (ATM) sales agreement with AC Sunshine Securities LLC under which the Company sold 39,248,940 Class A Ordinary Shares for gross proceeds of $30.97 million. While the primary disclosure is the termination, the material event is the dilutive equity issuance itself—a substantial unregistered offering that raised significant capital and diluted existing shareholders. The magnitude (39+ million shares, ~$31 million proceeds) and the ATM structure (characteristic of dilutive capital raises at smaller issuers) make this material to investors.
View raw filing on EDGAR →Freedom Holding Corp. is launching an offering of common stock for up to US$300 million pursuant to Regulation S, with bookbuilding commencing in mid-June 2026 at US$126.35 per share. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of share dilution and capital structure, even though it is being conducted offshore under Regulation S rather than as a registered domestic offering.
View raw filing on EDGAR →The Company entered into an at-the-market (ATM) equity distribution agreement on June 12, 2026, authorizing the sale of up to $250 million in common stock through multiple sales agents. This is a classic dilutive issuance under Rule 415 that would materially affect existing shareholders through potential equity dilution and is a significant capital-raising event for the registrant.
View raw filing on EDGAR →The filing discloses an unregistered issuance of 4,657,499 Class A ordinary shares to the Sponsor upon conversion of Class B shares, relying on Section 3(a)(9) exemption. While technically a conversion rather than a new issuance, this represents a material change in share structure and voting control—the Sponsor's converted shares now constitute approximately 21% of outstanding Class A shares (4.66M of 21.9M total). The event is material to investors assessing ownership concentration and governance, though the lack of cash proceeds and the pre-existing relationship with the Sponsor (as existing security holder) reduce the dilutive impact compared to a typical PIPE or private placement.
View raw filing on EDGAR →Universal Safety Products entered into a Securities Purchase Agreement to sell convertible promissory notes totaling up to $10.6 million principal to SJC Lending LLC under a Section 4(a)(2) private placement exemption. The conversion of these notes would result in issuance of shares exceeding 19.99% of outstanding common stock, requiring stockholder approval under NYSE American rules, representing a material dilutive equity issuance.
View raw filing on EDGAR →American Homes 4 Rent entered into an at-the-market (ATM) offering program on June 12, 2026, authorizing the sale of up to $1.0 billion in Class A common shares through multiple sales agents and forward sellers. The disclosure explicitly describes the mechanics of an ATM offering under Rule 415 of the Securities Act, including forward sale agreements that allow the company to borrow and sell shares before physical settlement. This is a material dilutive issuance that would affect shareholder equity and voting power.
View raw filing on EDGAR →The 6-K discloses a warrant inducement agreement dated June 12, 2026, whereby Rubico Inc. induced existing Class C warrant holders to exercise warrants at a reduced price ($0.95 to $0.65 per share), generating approximately $4.8 million in net proceeds. In exchange, the exercising holders receive new Class D Warrants to purchase up to 15,789,480 common shares in a private placement under Section 4(a)(2) of the Securities Act. This is a dilutive equity issuance—the company is issuing unregistered warrants (and the underlying common shares upon exercise) to raise capital, which will dilute existing shareholders' ownership and voting power. The filing explicitly discusses dilution risks and notes that as of the filing date, there will be 15,670,898 common shares outstanding plus substantial additional shares issuable under various warrants and convertible securities.
View raw filing on EDGAR →AmperCap completed an unregistered sale of equity securities, including the partial exercise of an over-allotment option generating $18.375 million in additional gross proceeds and private placement unit purchases by the Sponsor and underwriter representative totaling $551,250, resulting in aggregate capital of $144.8 million placed in trust.
View raw filing on EDGAR →Sanofi announced its 2026 global employee stock purchase plan (Action 2026), which will issue up to 9.8 million new shares to approximately 75,000 employees across 52 countries at a 20% discount to market price. The issuance represents material dilution to existing shareholders through increased share count and reduced earnings per share.
View raw filing on EDGAR →Beasley Broadcast Group entered into an Equity Distribution Agreement on June 12, 2026, establishing an at-the-market (ATM) offering program to sell up to $5.2 billion of Class A Common Stock through Noble Capital Markets. This is a classic dilutive equity issuance disclosed under Item 8.01, representing a material capital-raising activity that would affect shareholder equity and voting power.
View raw filing on EDGAR →Climb Bio entered into an Open Market Sale Agreement with Jefferies on June 12, 2026, authorizing the sale of up to $100 million in common stock through an at-the-market offering under Rule 415(a)(4), representing a registered dilutive equity issuance that materially affects shareholder ownership and capital structure.
View raw filing on EDGAR →Enliven Therapeutics entered into an underwriting agreement on June 11, 2026 for a registered public offering of 8,933,334 shares of common stock at $37.50 per share, plus 1,733,333 pre-funded warrants, with expected net proceeds of approximately $376 million (or $432.4 million if the underwriter option is exercised in full). The offering will dilute existing shareholders and materially affect the company's capital structure and ownership percentages.
View raw filing on EDGAR →Super Micro Computer entered into two material equity issuance agreements on June 10-11, 2026: an underwriting agreement to sell approximately 45.5 million shares of common stock (with a 30-day option for an additional 6.8 million shares) and an at-the-market (ATM) distribution agreement for up to $1.25 billion in aggregate sales proceeds. These offerings, including depositary shares representing Series A mandatory convertible preferred stock, represent significant dilutive capital raises that will materially affect existing shareholders' ownership percentages.
View raw filing on EDGAR →The 6-K announces a 1-for-20 reverse stock split effective June 16, 2026, approved by shareholders on April 29, 2026. While a reverse split is a capital structure event, it is not inherently dilutive in the traditional sense (no new shares are issued; existing shares are consolidated). However, reverse splits are often undertaken by companies facing delisting risk or trading below minimum price thresholds, signaling financial or operational stress. The announcement itself does not disclose the underlying reason or any material adverse event, making classification ambiguous—it could be `dilutive_issuance` (if interpreted broadly as a capital restructuring affecting share count), `governance_other` (a shareholder-approved corporate action), or `operational_other` (a strategic capital structure decision). Given the lack of explicit delisting-risk language and the absence of disclosed financial distress, and because reverse splits are routine capital management tools, this is best classified as a governance or operational matter rather than a material event, though the confidence is low due to the ambiguity.
View raw filing on EDGAR →The 6-K discloses a private placement (PIPE) of 2,968,747 Class A shares and 5,937,494 warrants at $1.28 per share/warrant pair, with warrants exercisable at a heavily discounted rate (20% of initial exercise price after 7 days, or exchangeable for 90% of underlying shares). This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D. The transaction also involves debt forgiveness (surrender of $3.8M loan) in exchange for the equity, further evidencing the dilutive nature and financial stress. Material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →This press release announces pricing of a registered direct offering of 1,133,332 Class A ordinary shares and pre-funded warrants to purchase 200,000 additional shares, raising approximately $2.0 million gross proceeds. The offering is registered under an effective Form F-3 shelf registration statement and involves dilutive equity issuance to new investors, which is a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →This exhibit discloses an agreement for the Company to issue $1,000,000 in aggregate principal amount of convertible promissory notes to accredited investors at a 10% discount ($900,000 purchase price). Convertible notes are dilutive securities that can convert to common shares, and the agreement also amends the conversion price floor to $1.875 per share. This is a private placement of convertible debt that will dilute existing shareholders upon conversion, fitting the dilutive_issuance category.
View raw filing on EDGAR →Unregistered sales of equity securities in connection with the Business Combination, including shares of New Quantum Space issued pursuant to Series A Stock Purchase Agreements and Series B pre-funded PIPE investments ($60 million) in convertible preferred units and warrants, all offered in reliance on Section 4(a)(2) exemption.
View raw filing on EDGAR →The Company entered into a Securities Purchase Agreement on June 5, 2026, and closed a private placement on June 12, 2026, issuing 5,000,000 Class A ordinary shares at US$0.12 per share for US$600,000 in aggregate proceeds. The shares were offered to non-U.S. persons under Regulation S and have not been registered under the Securities Act, with the Company committing to file a registration statement within 30 business days. This is a classic dilutive private placement that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →The company issued 2,250,000 warrants to the Sponsor in a private placement simultaneously with IPO closing, priced at $1.00 per warrant ($2.25 million aggregate) and exercisable at $11.50 per share, relying on Section 4(a)(2) exemption.
View raw filing on EDGAR →The Company filed an updated Prospectus Supplement on June 12, 2026, authorizing the sale of up to $13.4 million of common shares through an at-the-market (ATM) offering program with JonesTrading. ATM offerings represent dilutive equity issuances that can be executed at management's discretion, which is a material event requiring disclosure under Item 3.02 (or Item 8.01 as here). The specific dollar amount and mechanism indicate a material capital-raising activity.
View raw filing on EDGAR →JAB Acquisition Corp I completed a private placement of 260,000 units to the Sponsor at $10.00 per unit for $2.6 million in proceeds under Section 4(a)(2) of the Securities Act. The units consist of Class A Ordinary Shares, warrants, and rights to receive additional shares upon business combination completion.
View raw filing on EDGAR →This exhibit is a patent asset purchase agreement dated June 5, 2026, between Tianjin Qianli Culture Media Co., Ltd. (Party A) and Tianjin Information Sea Information Technology Co., Ltd. (Party B, a wholly owned subsidiary of DTSS). The agreement contemplates DTSS issuing Class A ordinary shares valued at RMB 7,000,000 (approximately USD equivalent) to two designated natural persons (Yang Zhaobing and Lü Hongwei) as consideration for the patent transfer. The agreement explicitly caps the issuance at 19.99% of DTSS's pre-issuance shares to avoid triggering Nasdaq's 20% shareholder approval rule, and each recipient is capped at 9.99% beneficial ownership. This is a classic dilutive equity issuance—unregistered restricted securities issued to third parties in exchange for assets, structured to avoid shareholder approval thresholds. The transaction is material to investors as it represents a significant equity dilution and capital raise mechanism.
View raw filing on EDGAR →The 6-K discloses issuance of a $2.0 million convertible note (the "Third Note") on June 5, 2026, convertible into Class B Ordinary Shares at $920 per $1,000 principal, plus a conditional commitment to issue an additional $11.0 million Fourth Note upon satisfaction of registration and Nasdaq compliance conditions. This is an unregistered private placement of convertible securities under Section 4(a)(2) and Regulation D, creating dilution to existing shareholders upon conversion. The amendment to the Securities Purchase Agreement restructures the facility and adds new issuance tranches, materially affecting the capital structure.
View raw filing on EDGAR →Smith Micro entered into inducement letter agreements to issue 487,349 unregistered Common Stock warrants at an exercise price of $3.80 per share in exchange for warrant holders exercising existing warrants at $3.35 per share, raising approximately $1.6 million in gross proceeds under Section 4(a)(2) and Rule 506 exemptions.
View raw filing on EDGAR →Capstone entered into an Amended and Restated Common Stock Purchase Agreement on June 11, 2026, establishing an equity line of credit permitting the sale of up to $20,000,000 in newly issued common stock to an accredited investor at 97% of VWAP, with up to 4,975,197 registered shares potentially dilutive to existing shareholders.
View raw filing on EDGAR →The registrant issued 15,000,000 unregistered shares of Common Stock to RagingBull Holders in connection with the merger, relying on Section 4(2) and Rule 506 exemptions, materially diluting existing shareholder equity and voting power.
View raw filing on EDGAR →The Company issued 865,903 unregistered shares of common stock in exchange for Series B Preferred Stock held by Streeterville Capital, LLC pursuant to Section 3(a)(9) exemption. This is a dilutive equity issuance that materially increases the common share count and would affect a reasonable investor's assessment of ownership dilution and voting power, particularly given the substantial number of shares issued relative to a small-cap issuer.
View raw filing on EDGAR →The filing discloses conversion of approximately $97.5 million in convertible notes into 7,649,523 shares of Class A Ordinary Common Stock on June 11, 2026, pursuant to Item 3.02. The Conversion Shares were issued unregistered under Section 4(a)(2) and Regulation D exemptions, representing a significant dilutive equity issuance that would materially affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →XCF Global entered into securities purchase agreements to issue 4,000,000 unregistered shares of Class A common stock for $600,000 in gross proceeds ($0.15/share) to accredited investors under Section 4(a)(2) and Regulation D Rule 506(b), with placement agent compensation of 7% cash fee (233,333 shares) plus 3% warrant coverage, creating material dilution to existing shareholders.
View raw filing on EDGAR →The 6-K discloses entry into Amendment No. 1 to an at-the-market (ATM) sales agreement dated June 11, 2026, which increases the aggregate offering price from $20 million to $60 million—a $40 million increase in authorized equity issuance. This is a material unregistered equity offering under Rule 415, with $9.3 million already sold as of April 1, 2026. The dilutive nature and capital-raising purpose are explicit, making this a dilutive_issuance event material to investors assessing the registrant's capitalization.
View raw filing on EDGAR →Arrive AI Inc. entered into an Equity Distribution Agreement with Maxim Group LLC on June 11, 2026, to sell up to $14,967,247 of common stock through an "at the market offering" program. This is a classic dilutive equity issuance under Item 1.01, where the company is authorized to raise capital by selling shares at market prices, with Maxim acting as sales agent at a 2.5% commission. The material amount and equity dilution to existing shareholders make this a reportable material event.
View raw filing on EDGAR →The filing discloses a registered direct offering of 311,876 common shares and a concurrent private placement of 311,876 warrants (exercisable at $4.008 per share for 5 years) for aggregate gross proceeds of approximately $1.25 million. Item 1.01 describes entry into a securities purchase agreement, and Item 3.02 explicitly addresses unregistered sales of equity securities. This is a classic dilutive equity issuance combining registered and unregistered securities, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →Venu Holding Corporation entered into an ATM (at-the-market) Sales Agreement with ThinkEquity LLC on June 12, 2026, authorizing the sale of up to $250 million in common stock shares. This is a dilutive equity issuance disclosed under Item 1.01 (Entry into a Material Definitive Agreement). ATM offerings are a classic signal of capital raising at small- and mid-cap issuers and would materially affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →Item 3.02 explicitly discloses an unregistered sale of equity securities (the "Company Shares") issued to Founding Shareholders in a transaction exempt from registration under Section 4(a)(2) and/or Regulation D. The shares are restricted securities under Rule 144. The reference to a Stock Purchase Agreement and the closing of a Purchase Agreement indicates a material equity issuance that would dilute existing shareholders.
View raw filing on EDGAR →The filing discloses a securities purchase agreement with 1800 Diagonal Lending for a convertible promissory note with an original issue discount and conversion rights at 61% of the lowest closing bid price over ten trading days, with potential conversion of up to 19.99% of outstanding shares. Item 3.02 explicitly addresses unregistered sales of equity securities under Section 4(a)(2) and Regulation D, and the conversion feature creates significant dilution risk to existing shareholders. This is a classic PIPE-like structure typical of distressed financing at small-cap issuers.
View raw filing on EDGAR →The company completed an unregistered private placement of 150,000 units to the Sponsor at $10.00 per unit ($1.5 million aggregate) pursuant to Section 4(a)(2) exemption, simultaneously with the IPO closing.
View raw filing on EDGAR →Avalo Therapeutics exchanged 4,294.675 shares of Series C Preferred Stock for newly created Series C-1 Preferred Stock in an unregistered transaction with an accredited investor, removing the 4.99% beneficial ownership restriction and allowing the investor to increase ownership to 9.99%. The Series C-1 Preferred Stock includes conversion rights (1,000 shares of Common Stock per preferred share), broad-based weighted average anti-dilution protection, and dividend parity, materially affecting shareholder concentration and dilution risk.
View raw filing on EDGAR →Trinity Biotech entered into an At the Market Offering Agreement with Lucid Capital Markets on June 12, 2026, authorizing the sale of up to $4,352,314 of American Depositary Shares (ADSs). This is a dilutive equity issuance under an ATM program, which allows the company to raise capital through the sale of registered securities at market prices. The filing discloses the material terms, including the 3.0% commission to the sales agent and the underlying registration statement (Form F-3 File No. 333-280391).
View raw filing on EDGAR →The filing discloses Amendment No. 2 to a warrant originally issued under a Securities Purchase Agreement dated March 17, 2026. The amendment reduces the exercise price from $16.00 to $3.00 per share for a 90-day period, substantially increasing the likelihood and incentive for exercise. This modification materially enhances the dilutive potential of the warrant and would affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →The exhibit discloses utilization of an "At the Market" (ATM) sales agreement with Cantor Fitzgerald & Co, announced December 17, 2024. Although no securities were actually issued during the reporting period (December 16, 2025 to June 12, 2026), the disclosure reports on the block admission of 4,000,000 depositary interests representing common shares available under the ATM scheme. ATM agreements represent standing authority to issue equity on a dilutive basis and are material capital-raising mechanisms, particularly for smaller issuers, even when no shares are issued in a given period.
View raw filing on EDGAR →The Company issued 132,803 shares of Common Stock (17.71% of outstanding shares) on June 6, 2026, as payment for an Option Fee under the Option Agreement, pursuant to Section 4(a)(2) of the Securities Act as an unregistered private placement to an accredited investor.
View raw filing on EDGAR →NEONC Technologies entered into a Securities Purchase Agreement to issue up to $5,000,000 of Series A Convertible Preferred Stock in a private placement to accredited investors under Section 4(a)(2) and Regulation D Rule 506 exemptions. The 6,000 shares of Series A Preferred Stock carry conversion rights into common stock at 80% of the lowest closing price during the five trading days prior to conversion, subject to a beneficial ownership limitation of 4.99% (or 9.99% upon election), resulting in material dilution to existing common shareholders.
View raw filing on EDGAR →